Latest News

The Role of Ambient AI in the Future of Specialty Care

The Role of Ambient AI in the Future of Specialty Care

For over a decade, the administrative burden in specialty medicine has quietly worsened. Orthopedic surgeons doing 40 patients a day are spending more time in the EHR than in the room. Ambient AI scribes have changed that equation in ways that are only beginning to...

read more

Latest News

Singapore Radiopharmaceutical Market: How H2 2026 Looks

Singapore Radiopharmaceutical Market: How H2 2026 Looks

The Singapore radiopharmaceutical market enters the second half of 2026 with more clinical capacity, more research output and a heavier regulatory calendar than at any previous point. New imaging infrastructure came online at the end of 2025, first-in-human data from...

read more
Why True Health Foods Need Evidence, Not Fashion

Why True Health Foods Need Evidence, Not Fashion

Functional foods have entered the mainstream, but adding a recognised ingredient is not the same as creating a credible product. A cardiologist argues that the category’s next phase will be won on scientific rationale, dose and honest communication, not on the length...

read more

Join The Future Of Life Sciences Media

 

In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters — all in real time.

 

 

Don’t wait for the media to pick up your story. Be the media.

More News

The Underestimated Occupational Impact of Pelvic Pain

The Underestimated Occupational Impact of Pelvic Pain

When people think about pelvic pain, they often think about symptoms. Cramping. Heavy bleeding. Fatigue. Bloating. Pain during intimacy. Bladder urgency. What is discussed far less is the occupational impact of pelvic pain: the way pain changes a person’s ability to...

read more
Clinical Trials Roundup | 29 May 2026

Clinical Trials Roundup | 29 May 2026

Apogee Therapeutics’ zumilokibart meets its primary and all secondary endpoints with high statistical significance in the Phase 2 APEX Part B trial for moderate-to-severe atopic dermatitis, TG Therapeutics’ BRIUMVI receives positive Phase 3 ENHANCE data supporting a...

read more
The Silent Clock in Your Arteries

The Silent Clock in Your Arteries

The Silent Clock in Your Arteries: Why Vascular Aging Is the Heart Health Crisis We're Missing We are living in an era of extraordinary innovation in heart health. Precision diagnostics. AI-guided therapies. Wearables that track everything from rhythm to recovery. And...

read more
Kailera Therapeutics IPO: A $625M Signal for Biotech

Kailera Therapeutics IPO: A $625M Signal for Biotech

When Kailera Therapeutics priced its initial public offering on 16 April 2026, it did more than raise money. The Kailera Therapeutics IPO set a new benchmark for an industry that had spent the better part of three years in the wilderness. Priced at $625 million, it...

read more
Climate-Sensitive Maternal Mental Health Screening

Climate-Sensitive Maternal Mental Health Screening

A pregnant woman may never walk into a clinic saying climate change is affecting her mental health. She may say she has not slept through the heat. She may say flooding made her miss an antenatal visit. She may say food costs have changed what she can feed her family....

read more
Biotech’s Missing Ingredient: Execution

Biotech’s Missing Ingredient: Execution

Biotech has never lacked scientific innovation. What the industry continues to underestimate is how difficult it is to turn promising science into an actual therapy that reaches patients.  Over the last several years, I have seen strong assets struggle for reasons...

read more
The Underestimated Occupational Impact of Pelvic Pain

The Underestimated Occupational Impact of Pelvic Pain

When people think about pelvic pain, they often think about symptoms. Cramping. Heavy bleeding. Fatigue. Bloating. Pain during intimacy. Bladder urgency. What is discussed far less is the occupational impact of pelvic pain: the way pain changes a person’s ability to...

read more
Clinical Trials Roundup | 29 May 2026

Clinical Trials Roundup | 29 May 2026

Apogee Therapeutics’ zumilokibart meets its primary and all secondary endpoints with high statistical significance in the Phase 2 APEX Part B trial for moderate-to-severe atopic dermatitis, TG Therapeutics’ BRIUMVI receives positive Phase 3 ENHANCE data supporting a...

read more
The Silent Clock in Your Arteries

The Silent Clock in Your Arteries

The Silent Clock in Your Arteries: Why Vascular Aging Is the Heart Health Crisis We're Missing We are living in an era of extraordinary innovation in heart health. Precision diagnostics. AI-guided therapies. Wearables that track everything from rhythm to recovery. And...

read more
Kailera Therapeutics IPO: A $625M Signal for Biotech

Kailera Therapeutics IPO: A $625M Signal for Biotech

When Kailera Therapeutics priced its initial public offering on 16 April 2026, it did more than raise money. The Kailera Therapeutics IPO set a new benchmark for an industry that had spent the better part of three years in the wilderness. Priced at $625 million, it...

read more
Climate-Sensitive Maternal Mental Health Screening

Climate-Sensitive Maternal Mental Health Screening

A pregnant woman may never walk into a clinic saying climate change is affecting her mental health. She may say she has not slept through the heat. She may say flooding made her miss an antenatal visit. She may say food costs have changed what she can feed her family....

read more
Biotech’s Missing Ingredient: Execution

Biotech’s Missing Ingredient: Execution

Biotech has never lacked scientific innovation. What the industry continues to underestimate is how difficult it is to turn promising science into an actual therapy that reaches patients.  Over the last several years, I have seen strong assets struggle for reasons...

read more

Featured Articles

FDA building exterior alongside pharmaceutical laboratory setting representing drug approval decisions

FDA Drug Approval Decisions

Last updated 31 July 2026. Covering target action dates from August to December 2026. The closing stretch of the third quarter has become the busiest regulatory window of 2026. Between early August and the end of September, the US Food and Drug Administration faces...
Pipette dispensing into lab vials with glowing DNA helix and genetic sequence data for Life Science Daily News

Life Science Daily News: Eight Months of Growth and a Global Community Taking Shape

Life Science Daily News launched in November 2025 with a simple premise: that researchers, biotech founders, healthcare professionals, communications specialists and industry professionals should be able to publish their own work directly to a specialist audience,...
gloved hands holding a glowing blue sample vial (labelled LOT: 24-B1, SAMPLE: GENO-) with a lab researcher working in the background.

CRISPR Gene Editing 2026: Rare Diseases, Cancer and Autoimmune

CRISPR gene editing in 2026 is no longer a technology to watch. It is a technology delivering results. Across three distinct disease areas, rare inherited conditions, haematologic and solid cancers, and autoimmune disease, clinical programmes are accumulating...
Three GLP-1 drug pipeline injection pens and oral tablets beside a clinical trial efficacy chart on a clipboard

The GLP-1 Drug Pipeline: Every Candidate to Watch in 2026

The GLP-1 drug pipeline has become one of the most consequential and closely watched in modern pharmaceutical history. In 2026, the class of glucagon-like peptide-1 receptor agonists is no longer defined solely by Ozempic and Wegovy. A new generation of oral tablets,...
Sjögren's disease diagnosis: close-up of a dry, irritated eye with eye drops being applied

Anti-Ro52 vs Anti-Ro60: Advancing Sjögren’s Disease Diagnosis

Autoantibody testing is a central part of autoimmune disease diagnosis, including Sjögren’s disease (SjD). The American College of Rheumatology and European Alliance of Associations of Rheumatology (ACR/EULAR) classification criteria for SjD incorporate ocular and...

Further News

Weekly News Roundup | 25 May 2026

Weekly News Roundup | 25 May 2026

Life science news 25 May 2026: Lilly's retatrutide delivers bariatric-surgery-level weight loss in Phase 3, two landmark FDA approvals reshape oncology and hepatology, and a UK biotech targets the global AMR crisis. The week of 17 to 24 May 2026 delivered a dense...

read more
Clinical Trials Roundup | 22 May 2026

Clinical Trials Roundup | 22 May 2026

Merck's sacituzumab tirumotecan meets both primary endpoints in the pivotal Phase 3 TroFuse-005 trial for advanced endometrial cancer, Relay Therapeutics reports the first clinical evidence of PI3Kα mutant-selective inhibition in PIK3CA-driven vascular anomalies in...

read more
Oral vs Injectable GLP-1s: The 2026 Weight Loss Drug Shift

Oral vs Injectable GLP-1s: The 2026 Weight Loss Drug Shift

The arrival of two approved oral GLP-1 weight loss therapies in the space of four months has fundamentally redrawn the obesity treatment landscape in 2026. For years, the question of whether a daily pill could ever match the efficacy of a weekly injection was largely...

read more
Why Neurology Clinical Trials Need Purpose-Built AI

Why Neurology Clinical Trials Need Purpose-Built AI

Each year on May 20, International Clinical Trials Day recognizes James Lind’s 1747 scurvy trial and the patients, clinicians, coordinators, sponsors and researchers who make clinical progress possible. It is also a moment to look honestly at where clinical research...

read more
What the Veppanu Approval Means for ESR1 Breast Cancer

What the Veppanu Approval Means for ESR1 Breast Cancer

The FDA's approval of Veppanu (vepdegestrant) marks the first regulatory clearance for a PROTAC in any disease area, and opens a new chapter in the treatment of ESR1-mutated advanced breast cancer. On 1 May 2026, the United States Food and Drug Administration approved...

read more
Agentic AI in Drug Discovery: Why Big Pharma is All in

Agentic AI in Drug Discovery: Why Big Pharma is All in

When Eli Lilly signed a deal worth up to $2.75 billion with AI drug developer Insilico Medicine in March 2026, it was the latest in a cascade of nine-figure and ten-figure commitments from the world’s largest pharmaceutical companies to a single emerging technology....

read more

Further News

Digital Twin: The Future of Pharmaceutical Manufacturing Science

Pharmaceutical manufacturing is entering a new scientific era. For decades, the industry has relied on validated processes, fixed control strategies, laboratory testing and carefully documented batch records to prove that medicines are made consistently and safely....

How AI-Enabled Functional Precision Oncology Is Personalizing Treatment

When the Standard Playbook Runs Out  In pediatric and adult oncology alike, there is a recognizable moment when the standard treatment playbook is exhausted. For patients with rare, relapsed, or treatment-resistant cancers, guidelines built for the common case offer...

The Infrastructure Gap Behind the GLP-1 Boom

The rapid rise of GLP-1 medications has transformed healthcare delivery in ways few therapeutic categories have achieved in recent decades. Originally developed to help manage type 2 diabetes, GLP-1 receptor agonists such as semaglutide and tirzepatide have become...

How Climate Change is Redrawing Europe’s Disease Landscape

The impact of climate change is usually discussed in terms of heatwaves and floods. While less visible, its impact on infectious diseases is equally consequential for public health.  New data from the UK Health Security Agency (UKHSA) showing a surge in chikungunya...

A Path to Rebuilding American Manufacturing for Lab Consumables

Amid today's geopolitical tensions, supply chain vulnerability is emerging as an increasingly central concern, and, in the case of life science consumables, one that places the health of the public at risk. The issue itself, however, is far from new. In December 2020...

Weekly News Roundup | 13 July 2026

Life science news 13 July 2026: Vertex seals a $10 billion deal for rare endocrine specialist Crinetics, the FDA clears the first dual BAFF/APRIL inhibitor for IgA nephropathy, and Novartis acquires a UK cancer therapy spinout in a blockbuster week for pharma, biotech...

Medicare GLP-1 Bridge: Who Qualifies and Who Does Not

The Medicare GLP-1 Bridge launched on 1 July 2026, opening a new pathway for eligible Medicare Part D beneficiaries to access weight management medications at a fixed monthly copay of $50. For clinicians navigating GLP-1 Bridge eligibility criteria, the prior...

The Next Public Health Playbook: Why Trust Matters More Than Ever

The current news cycle is dominated by new and exotic-sounding organisms and chemicals: PFOS, bisphenols, phthalates, Mpox, New World screwworm, Andes hantavirus, Ebola bundibugyo, Borrelia burgdorferi, dengue, and chikungunya. What do they have in common? They are...

Clinical Trials Roundup | 10 July 2026

Roche’s divarasib demonstrates superiority over approved KRAS G12C inhibitors in the Phase 3 Krascendo 1 head-to-head lung cancer trial, Vera Therapeutics’ Trutakna receives FDA accelerated approval as the first BAFF/APRIL inhibitor for IgA nephropathy, Rhythm...

Adipose Tissue Isn’t Just Storage: Fat as an Endocrine and Immune Organ

For much of the 20th century, body fat was viewed mainly as the body's energy reservoir—a passive tissue that stored excess calories for future use. While this remains an important function of adipose tissue, research over the past few decades has revealed a far more...

FDA Drug Approval Decisions to Watch: July and August 2026

The second half of 2026 is shaping up to be one of the most consequential periods for FDA drug approval decisions in recent memory. Between mid-July and late August, the US Food and Drug Administration faces a succession of Prescription Drug User Fee Act target action...

New Research On the Next Phase in Protecting Muscle During GLP-1 Treatment

When I wrote previously for this publication about the gap between GLP-1 prescribing rates and the clinical conversation around lean muscle preservation, the argument centred on a simple premise: weight loss is not fat loss, and the clinical infrastructure around...

Want to Be Part of the Next Chapter in Life Sciences Media?

 

LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

 

 

Don’t wait for the media to pick up your story. Be the media.

See More Articles

Want to Be Part of the Next Chapter in Life Sciences Media?

 

LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

 

 

Don’t wait for the media to pick up your story. Be the media.